Projects per year
Abstract
Unlike conventional controlled drug delivery systems where drug is released at a constant pre-programmed rate, drug release from conducting polymers (CPs) can be controlled through electrical stimuli and adjusted based on the patient's needs. However, owing to their low drug loading capacity and limited electrical responsiveness CP systems cannot currently be applied for systemic drug delivery or to treat chronic disease. To overcome that obstacle one approach is to fabricate porous CP structures. In this work, polypyrrole (PPy) was used owing to its electrical responsiveness and biocompatibility. Liquid crystals were used as a template through which PPy was grown. Dexamethasone phosphate was loaded as a dopant into PPy during polymerisation and its release was quantified by HPLC after the removal of liquid crystal; release could be modified by electrical stimulus. This system has potential applications in conditions where required drug dosing changes with time, such as in age-related macular degeneration.
Original language | English |
---|---|
Pages (from-to) | 422-431 |
Number of pages | 10 |
Journal | International Journal of Nanotechnology |
Volume | 14 |
Issue number | 1-6 |
DOIs | |
Publication status | Published - 2017 |
Keywords
- Conducting polymer
- Lyotropic liquid crystal
- Phase transition
- Polypyrrole
- SAXS
- Scanning electron microscopy
- SEM
- Small angle X-ray scattering
- Stimuli responsive drug delivery system
Projects
- 1 Finished
-
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
Davis, T. (Primary Chief Investigator (PCI)), Boyd, B. (Chief Investigator (CI)), Bunnett, N. (Chief Investigator (CI)), Porter, C. (Chief Investigator (CI)), Caruso, F. (Chief Investigator (CI)), Kent, S. (Chief Investigator (CI)), Thordarson, P. (Chief Investigator (CI)), Kearnes, M. (Chief Investigator (CI)), Gooding, J. (Chief Investigator (CI)), Kavallaris, M. (Chief Investigator (CI)), Thurecht, K. J. (Chief Investigator (CI)), Whittaker, A. K. (Chief Investigator (CI)), Parton, R. (Chief Investigator (CI)), Corrie, S. R. (Chief Investigator (CI)), Johnston, A. (Chief Investigator (CI)), McGhee, J. (Chief Investigator (CI)), Greguric, I. D. (Partner Investigator (PI)), Stevens, M. M. (Partner Investigator (PI)), Lewis, J. S. (Partner Investigator (PI)), Lee, D. S. (Partner Investigator (PI)), Alexander, C. (Partner Investigator (PI)), Dawson, K. (Partner Investigator (PI)), Hawker, C. (Partner Investigator (PI)), Haddleton, D. (Partner Investigator (PI)), Thierry, B. (Chief Investigator (CI)), Prestidge, C. A. (Chief Investigator (CI)), Meyer, A. (Project Manager), Jones-Jayasinghe, N. (Project Manager), Voelcker, N. (Chief Investigator (CI)), Nann, T. (Chief Investigator (CI)) & McLean, K. (Partner Investigator (PI))
ARC - Australian Research Council, Monash University, University of Melbourne, University of New South Wales (UNSW), University of Queensland , University of South Australia, Monash University – Internal Faculty Contribution, University of Wisconsin Madison, Memorial Sloan Kettering Cancer Center, University of California System, University College Dublin, Imperial College London, University of Warwick, Sungkyunkwan University, Australian Nuclear Science and Technology Organisation (ANSTO) , University of Nottingham
30/06/14 → 29/06/21
Project: Research